Client Profile
Series B biotech startup with a platform technology applicable across immunology, oncology, and rare diseases.
The challenge: The leadership team was divided on which indication to pursue first for Phase II, with $40M run rate on the line. Internal data was inconclusive.
The solution: Pharaon facilitated 25 anonymous KOL (Key Opinion Leader) interviews covering practicing physicians, payors, and former FDA reviewers across all three therapeutic areas.
Results
- Clear consensus emerged for the rare disease indication — fastest path to approval with strongest pricing power
- Board unanimously approved the pivot
- Strategic partnership signed 6 weeks later at a 30% premium to pre-pivot valuation
